Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05779813

Genetic Frontotemporal Dementia Initiative for Neurodevelopment

This is an international multi-centre cohort study of first and second degree family members of individuals who carry Frontotemporal Dementia (FTD) mutations in MAPT, GRN or C9ORF72 repeat expansions for youths between the ages 9-17.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Western University

London, Ontario, N6A 3K7, Canada

Location status: Recruiting

Location contact

Kristy Coleman, MSc

CONTACT

[email protected]

661-2111

About this study

GENFI-NeuroDev will study genetic FTD and its associated disorders (including Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis(ALS)) in members of families with a known mutation in GRN or MAPT or an expansion in C9orf72. Participants with at-risk members of families (first-degree and second-degree relatives of known genetic mutation carriers). All GENFI-NeuroDev participants will be assessed longitudinally with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols. Parents or guardians of potential GENFI NeuroDev participants are all aware of the autosomal dominant genetic nature of FTD in their family prior to being approached for potential participation in this study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent must be obtained and documented (from the participant and their substitute decision maker). This can be obtained in person or remotely.
  • Youths between the ages of 9 and 16 inclusive at time of enrollment, followed until age 17.
  • Youths must have a 1st or 2nd degree biological relative who has participated (past or present) in the Genetic Frontotemporal Dementia Initiative (GENFI) study or with genetic FTD (i.e. a known mutation in biological parent or grandparent).
  • Parent(s)/guardian deem appropriate to participate.
  • Must have a study partner who can participate as required in the protocol (provide corroborative information). Study partner must have regular contact with the participant and must be parent/guardian of this participant.
  • Must have age-appropriate awareness that FTD runs in their family as determined by local PI.

Exclusion criteria

  • Current structural brain abnormality affecting cognition or behaviour not thought to be possibly related to genetic FTD that would prevent completion of study assessments (such as brain tumor, stroke, hydrocephalus).
  • Other concerns that participation in the study may not be in the best interest of the youth or parent, as raised by the participant's parent/guardian/primary care provider, local site PI or psychologist.
  • Lack of study partner.
  • For MRI: meeting any MRI incompatible criteria. Note: Participants may opt to decline MRI scans and complete the other measures.

Treatment and study plan

Primary outcomes

  1. Brain development as measured by structural and functional Magnetic Resonance Imaging

    Time frame: Through study completion, an average of 2 years

Other outcomes

  1. Fluid biomarkers of neurodevelopment, neurodegeneration and inflammation

    Time frame: Through study completion, an average of 2 years

    To examine differences compared to age matched non-carriers in physiologic signals in fluid biomarkers of synaptic markers, axonal markers, and neuroinflammation markers.

  2. Resting State quantitative electroencephalogram (EEG)

    Time frame: Through study completion, an average of 2 years

    To analyze resting state quantitative EEG (qEEG) power spectral density, a reliable metric of CNS physiology in children.

Study contacts

Contact information is provided by the study sponsor or research team.

Kristy Coleman

CONTACT

[email protected]

519-646-6100

Sponsors and collaborators

Lead sponsor

Western University

Other

Registry information

Acronym: GENFI-NeuroDev

Important dates

Study start
2023
Primary completion
2033
Study completion
2035
First posted
Mar 22, 2023
Registry last updated
Apr 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.